Transforming life for patients with Parkinson’s disease

Developing novel treatments for Parkinson’s disease, driving change for patients with the most troublesome symptoms: involuntary movements occurring upon long-term use of levodopa (LIDs) and impaired balance leading to falls.

Two clinical phase II candidates

Mesdopetam (IRL790) in development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease. Read more >

IRL752 in development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease. Read more >

Proprietary technology platform

The research and development program is generated by the proprietary technology platform, the Integrative Screening Process (ISP). Read more >

Annual General Meeting 2020

IRLAB held the annual general meeting 2020 on May 7. Read more >

Latest press release

IRLABs mesdopetam presenteras på omslaget av topprankade vetenskapliga tidskriften JPET

June 24, 2020

IRLAB meddelade idag att den högt rankade tidskriften JPET presenterar IRLABs läkemedelskandidat mesdopetam (IRL790) på omslaget av senaste numret, 1 juli 2020. På omslaget illustreras hur mesdopetam binder till dopamin D3-receptorn. I den vetenskapliga artikeln beskrivs även läkemedelskandidatens gynnsamma effekter på systemnivå i hjärnan. Mesdopetam utvecklas för behandling av motoriska och psykiatriska symtom vid Parkinsons sjukdom.

Read More >
Latest presentation

Nicholas Waters, CEO, presents at Redeye’s Growth Day 2020

June 2, 2020 Read More >